Arbutus Biopharma (ABUS) 10-Q2021 Q1 Quarterly report

Filed: 5 May 21, 4:29pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: analog, argument, attaching, boost, burn, cap, Codification, competitive, conform, contest, Creating, defective, DEL, final, forward, frequency, GmbH, greatly, guided, infrequently, intention, library, lockup, main, member, Mpro, organizational, pending, plasma, plateau, premium, prevent, prohibited, quantifiable, rapid, reached, reclassified, reconsent, repeat, resolution, resolved, restructuring, robust, satisfaction, schedule, scheduled, supplement, thought, unquantifiable, vigorously

Removed: accrue, achieved, achievement, Acrotech, AEs, allegedly, ALT, alter, anticipate, AST, asymptomatic, banking, billed, Burnaby, Canada, cancer, choose, claimed, clinically, commenced, compelled, compelling, conducting, confidence, Conversely, converted, Counterclaim, cured, death, defense, denominated, depend, diagnosed, die, dilutive, discontinue, distancing, Distinguishing, divided, dollar, elevation, employee, ending, evolve, expedite, experienced, expired, facility, feel, feet, filing, flare, forced, furlough, geographic, hiring, hourly, importantly, imposed, inform, injection, interferon, internally, interruption, involving, joined, laboratory, lag, lease, list, local, long, manufacturing, Marqibo, matured, mild, monotherapy, Notably, objective, occurred, oligonucleotide, opportunity, originally, par, parameter, pay, pegylated, performing, permanent, preclinical, predicted, proportion, proportionate, publicly, quarantine, receipt, recommended, recruiting, reflective, relevant, rest, reversible, revised, SE, secretion, shipping, social, Spectrum, spend, square, state, sublease, sublicense, suffer, surfaced, temporary, thousand, Today, TPC, training, tranche, transitional, twelve, uncertain, undetectable, unexpected, unmet, unrelated, unspecified, updated, vital, wide, window, working, worldwide, wrongly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated ABUS transcripts

ABUS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I David Hastings, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.

Date: May 5, 2021


			/s/ David Hastings
			Name: David Hastings
			Title: Chief Financial Officer